Abstract
Background KRAS-mutated non-small cell lung cancer (NSCLC) is associated with a poor prognosis to standard therapies. Despite advances of immune checkpoint inhibitors (ICIs), not all patients show durable responses. In this study, we aim to identify associations between ICI-response and the gut microbiome in patients with KRAS-mutated NSCLC.
Methods We performed shotgun metagenomic sequencing of stool samples collected before ICI initiation from 33 patients with KRAS-mutated NSCLC. Microbiome composition within (α-diversity) and between samples (β-diversity) was calculated using Shannon diversity index and principal component analysis on Aitchison distances, respectively. A Bayesian logistic-normal regression model (Pibble) was implemented to identify associations between gut microbial features and disease control rate (DCR), progression free survival at 12 months (PFS12) and immune related adverse events (irAEs), adjusting for ICI-regimen, metastatic disease stage, age, sex and BMI.
Results Responders were enriched with several saccharolytic species, including Agathobaculum butyriciproducens, Fusicatenibacter saccharivorans, Bifidobacterium longum and Eubacterium ramulus. Non-responders harbored higher abundances of several Bacteroides and Blautia species. Patients unaffected by irAEs demonstrated higher abundances of biotin and butyrate synthesis pathways. Development of irAEs was associated with higher Alistipes finegoldii, Bifidobacterium longum and Bacteroides uniformis abundance. No differences were observed between responders and non-responders in Shannon diversity index (P=0.69) and overall microbial composition (P=0.82).
Conclusions We show gut microbial species and pathways that are differentially abundant between responders and non-responders to ICI in the setting of KRAS-mutated NSCLC. We find overlap with microbial signatures of response to ICI in other tumor types, potentially reflecting tumor-independent microbial mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by research grants of Bristol-Myers Squibb; CheckMate CA209-759; NTR 6158 (Dutch Trial Register). A grant from the SEERAVE Foundation was to support LAB, JRB, RKW and GAPH. RG is funded by a research collaboration grant (between UMCG & Janssen Pharmaceuticals Ltd. R&D.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO). The Medical Ethical Board of the University Medical Center Groningen approved the study protocol (CA209-759), NTR 6158 (Dutch Trial Register). All patients provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Take-home message: The gut microbiome could be a target to improve outcomes in advanced non-small cell lung cancer patients harbouring a KRAS-mutation treated with immune checkpoint inhibitors.
Ethical Approval The study was conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO). The Medical Ethical Board of the University Medical Center Groningen approved the study protocol (CA209-759), NTR 6158 (Dutch Trial Register). All patients provided written informed consent.
Data availability All relevant data supporting the key findings of this study are available within the article and the supplementary files. Codes used for generating the microbial profiles are publicly available at: [https://github.com/WeersmaLabIBD/Microbiome/blob/master/Protocol_metagenomic_pipeline.md]. All statistical analysis scripts are written in R and can be found here: https://github.com/WeersmaLabIBD/Microbiome
Data Availability
All relevant data supporting the key findings of this study are available within the article and the supplementary files. Codes used for generating the microbial profiles are publicly available at [https://github.com/WeersmaLabIBD/Microbiome/blob/master/Protocol_metagenomic_pipeli ne.md]. All statistical analysis scripts are written in R and can be found here: https://github.com/WeersmaLabIBD/Microbiome
https://github.com/WeersmaLabIBD/Microbiome/blob/master/Protocol_metagenomic_pipeline.md
